source
- Crystalys gets $130M to take Sobi-rivaling gout drug to marketA San Diego biotech has raised an additional $130 million to get a gout drug that's already approved in Japan and China onto the US and European markets. Crystalys Therapeutics reeled in the Series…Endpoints · 7d ago↗ source
- Job dissatisfaction and health care access uncertainty grows in the U.S., new study findsWhat Hawaii's wildfires can teach the nation about health recovery, 4.5 million people disenrolled from SNAP, and more health newsSTAT · 7d ago↗ source
- Summit reports two-year survival data for Western patients, though context lackingSummit Therapeutics unveiled additional follow-up data on its experimental cancer drug ivonescimab, and how its benefit compares between Asian and Western patients. But key context remains unknown.…